Homozygous protein C deficiency

Observations on the nature of the molecular abnormality and the effectiveness of warfarin therapy

C. Peters, James F Casella, R. A. Marlar, R. R. Montgomery, W. H. Zinkham

Research output: Contribution to journalArticle

Abstract

An infant with severe homozygous protein C deficiency was brought to medical attention because of purpura fulminans and severe bilateral vitreous hemorrhages in the neonatal period. Infusions of fresh frozen plasma were given for 8 months. On two occasions, attempts to decrease the frequency of fresh frozen plasma infusions to less than twice a day led to episodes of microangiopathic hemolysis, fibrinolysis, and acute renal failure. Infarction of skin and subcutaneous tissues did not recur. Both episodes were controlled after reinstitution of fresh frozen plasma. Complications of therapy with fresh frozen plasma included hyperproteinemia and hypertension. Warfarin therapy was instituted when the baby was 8 months of age, followed by a gradual withdrawal of fresh frozen plasma therapy. The dose of warfarin required to maintain the prothrombin time in a range of 1.8 to 2.2 times normal varied considerably during short periods, a phenomenon that may have been due to several factors: hypercatabolism of the drug with prolonged administration, abnormality of liver function, variation in levels of serum albumin, fluctuations in drug dosage secondary to oral administration, and variations in dietary vitamin K. Protein C determinations of immunologic and functional assays consistently showed detectable but reduced protein C antigen levels with undetectable activity levels, suggesting that a dysproteinemia rather than a deficiency of synthesis is responsible for the child's coagulopathy.

Original languageEnglish (US)
Pages (from-to)272-276
Number of pages5
JournalPediatrics
Volume81
Issue number2
StatePublished - 1988

Fingerprint

Protein C Deficiency
Warfarin
Protein C
Purpura Fulminans
Therapeutics
Vitreous Hemorrhage
Vitamin K
Prothrombin Time
Subcutaneous Tissue
Fibrinolysis
Hemolysis
Acute Kidney Injury
Serum Albumin
Pharmaceutical Preparations
Infarction
Oral Administration
Hypertension
Antigens
Skin
Liver

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Homozygous protein C deficiency : Observations on the nature of the molecular abnormality and the effectiveness of warfarin therapy. / Peters, C.; Casella, James F; Marlar, R. A.; Montgomery, R. R.; Zinkham, W. H.

In: Pediatrics, Vol. 81, No. 2, 1988, p. 272-276.

Research output: Contribution to journalArticle

Peters, C. ; Casella, James F ; Marlar, R. A. ; Montgomery, R. R. ; Zinkham, W. H. / Homozygous protein C deficiency : Observations on the nature of the molecular abnormality and the effectiveness of warfarin therapy. In: Pediatrics. 1988 ; Vol. 81, No. 2. pp. 272-276.
@article{9350b9de0cdb4c5e85eb6509d8c9713f,
title = "Homozygous protein C deficiency: Observations on the nature of the molecular abnormality and the effectiveness of warfarin therapy",
abstract = "An infant with severe homozygous protein C deficiency was brought to medical attention because of purpura fulminans and severe bilateral vitreous hemorrhages in the neonatal period. Infusions of fresh frozen plasma were given for 8 months. On two occasions, attempts to decrease the frequency of fresh frozen plasma infusions to less than twice a day led to episodes of microangiopathic hemolysis, fibrinolysis, and acute renal failure. Infarction of skin and subcutaneous tissues did not recur. Both episodes were controlled after reinstitution of fresh frozen plasma. Complications of therapy with fresh frozen plasma included hyperproteinemia and hypertension. Warfarin therapy was instituted when the baby was 8 months of age, followed by a gradual withdrawal of fresh frozen plasma therapy. The dose of warfarin required to maintain the prothrombin time in a range of 1.8 to 2.2 times normal varied considerably during short periods, a phenomenon that may have been due to several factors: hypercatabolism of the drug with prolonged administration, abnormality of liver function, variation in levels of serum albumin, fluctuations in drug dosage secondary to oral administration, and variations in dietary vitamin K. Protein C determinations of immunologic and functional assays consistently showed detectable but reduced protein C antigen levels with undetectable activity levels, suggesting that a dysproteinemia rather than a deficiency of synthesis is responsible for the child's coagulopathy.",
author = "C. Peters and Casella, {James F} and Marlar, {R. A.} and Montgomery, {R. R.} and Zinkham, {W. H.}",
year = "1988",
language = "English (US)",
volume = "81",
pages = "272--276",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "2",

}

TY - JOUR

T1 - Homozygous protein C deficiency

T2 - Observations on the nature of the molecular abnormality and the effectiveness of warfarin therapy

AU - Peters, C.

AU - Casella, James F

AU - Marlar, R. A.

AU - Montgomery, R. R.

AU - Zinkham, W. H.

PY - 1988

Y1 - 1988

N2 - An infant with severe homozygous protein C deficiency was brought to medical attention because of purpura fulminans and severe bilateral vitreous hemorrhages in the neonatal period. Infusions of fresh frozen plasma were given for 8 months. On two occasions, attempts to decrease the frequency of fresh frozen plasma infusions to less than twice a day led to episodes of microangiopathic hemolysis, fibrinolysis, and acute renal failure. Infarction of skin and subcutaneous tissues did not recur. Both episodes were controlled after reinstitution of fresh frozen plasma. Complications of therapy with fresh frozen plasma included hyperproteinemia and hypertension. Warfarin therapy was instituted when the baby was 8 months of age, followed by a gradual withdrawal of fresh frozen plasma therapy. The dose of warfarin required to maintain the prothrombin time in a range of 1.8 to 2.2 times normal varied considerably during short periods, a phenomenon that may have been due to several factors: hypercatabolism of the drug with prolonged administration, abnormality of liver function, variation in levels of serum albumin, fluctuations in drug dosage secondary to oral administration, and variations in dietary vitamin K. Protein C determinations of immunologic and functional assays consistently showed detectable but reduced protein C antigen levels with undetectable activity levels, suggesting that a dysproteinemia rather than a deficiency of synthesis is responsible for the child's coagulopathy.

AB - An infant with severe homozygous protein C deficiency was brought to medical attention because of purpura fulminans and severe bilateral vitreous hemorrhages in the neonatal period. Infusions of fresh frozen plasma were given for 8 months. On two occasions, attempts to decrease the frequency of fresh frozen plasma infusions to less than twice a day led to episodes of microangiopathic hemolysis, fibrinolysis, and acute renal failure. Infarction of skin and subcutaneous tissues did not recur. Both episodes were controlled after reinstitution of fresh frozen plasma. Complications of therapy with fresh frozen plasma included hyperproteinemia and hypertension. Warfarin therapy was instituted when the baby was 8 months of age, followed by a gradual withdrawal of fresh frozen plasma therapy. The dose of warfarin required to maintain the prothrombin time in a range of 1.8 to 2.2 times normal varied considerably during short periods, a phenomenon that may have been due to several factors: hypercatabolism of the drug with prolonged administration, abnormality of liver function, variation in levels of serum albumin, fluctuations in drug dosage secondary to oral administration, and variations in dietary vitamin K. Protein C determinations of immunologic and functional assays consistently showed detectable but reduced protein C antigen levels with undetectable activity levels, suggesting that a dysproteinemia rather than a deficiency of synthesis is responsible for the child's coagulopathy.

UR - http://www.scopus.com/inward/record.url?scp=0023911084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023911084&partnerID=8YFLogxK

M3 - Article

VL - 81

SP - 272

EP - 276

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 2

ER -